Pseudovirus News and Research

RSS

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Researchers evaluated the humoral and cellular immune memory induced by four COVID-19 vaccines representing three different vaccine platforms.

24 Mar 2022

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Researchers discuss alternate therapeutic targets for treating COVID-19 and the effects of Gal-9 on SARS-CoV-2 infection and the immune response.

23 Mar 2022

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

A recent study finds that there is no considerable B-cell immunity against SARS-CoV-2 in unexposed healthy individuals.

23 Mar 2022

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

In a new study, researchers discovered human monoclonal antibodies, which were specific and potent against the severe acute respiratory syndrome coronavirus 2 Omicron variant.

23 Mar 2022

Importance of Numb-associated kinases in SARS-CoV-2 infection

A new study posted to the bioRxiv* preprint server has focussed on assessing four members of the NAK family that are associated with SARS-CoV-2 infection. These kininases could act as a target for the development of effective COVID-19 therapeutics.

23 Mar 2022

SARS-CoV-2 nanobody that binds to the receptor-binding domain could prevent COVID-19 in animals

A new study assessed the potential of a nanobody – directly prepared by binding to SARS-CoV-2 spike receptor-binding domain protein, in the treatment of COVID-19.

22 Mar 2022

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Researchers evaluated the importance of the Ex3Lx6L motif in SARS-CoV-2 entry into host cells mediated by the spike protein syncytium formation and membrane fusion.

22 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Researchers demonstrate the broad neutralization potential of a strategically engineered circRNA using mice as a model system.

21 Mar 2022

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Researchers evaluated the immune responses in individuals vaccinated with the BNT162b2 vaccine.

21 Mar 2022

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Researchers developed covalent nanobodies to neutralize severe acute respiratory syndrome coronavirus-2 and its variants.

18 Mar 2022

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

Researchers reported an epitope with high potency and breadth and demonstrated that a therapeutic antibody directed at this site neutralizes all SARS-CoV-2 variants.

18 Mar 2022

The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

Researchers compared the efficacy of booster doses of heterologous intramuscular and aerosolized adenovirus-vectored vaccine, a recombinant protein-based ZF2001 vaccine, and homologous CoronaVac vaccines.

17 Mar 2022

Pseudovirus News and Research

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Researchers investigate Galectin-9 as a new treatment target for COVID-19

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

Importance of Numb-associated kinases in SARS-CoV-2 infection

SARS-CoV-2 nanobody that binds to the receptor-binding domain could prevent COVID-19 in animals

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Study explores SARS-CoV-2 spike epitope with potent and broad neutralization

The immunogenicity of homologous and heterologous boosters in adults who received inactivated COVID-19 vaccine six months prior

Ethyl lauroyl arginine hydrochloride (ELAH) nasal spray as potent antiviral against SARS-CoV-2

Study explores neutralization of SARS-CoV-2 Omicron variant by subunit vaccine boosters

Factors influencing cross-protective serological immunity against SARS-CoV-2 variants in Asians

Potent pan-β-CoV human monoclonal antibody has in vivo activity in multiple animal models

Natural SARS-CoV-2 infection-induced anti-spike antibody responses

Cross-species infectivity of SARS-CoV-2 variants correlated with prevalence

Identification of a rapid test for SARS-CoV-2 neutralization via antibodies and nanobodies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News